Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 16:05 ET | Source: GeneDx Holdings Corp.

GeneDx to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

STAMFORD, Conn., April 18, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release...
March 16, 2023 08:45 ET | Source: GeneDx Holdings Corp.

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

STAMFORD, Conn., March 16, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, announced new...
January 30, 2023 08:30 ET | Source: GeneDx Holdings Corp.

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype...
January 09, 2023 08:30 ET | Source: GeneDx Holdings Corp.

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company’s common stock will trade on the Nasdaq under...
December 05, 2022 08:00 ET | Source: Sema4

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings...
October 31, 2022 09:00 ET | Source: Sema4

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome...
October 26, 2022 08:00 ET | Source: Sema4

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing...
October 13, 2022 08:00 ET | Source: Sema4

Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child...
December 04, 2012 08:36 ET | Source: Invivoscribe

Invivoscribe Launches Genection, a New Personalized Molecular Medicine Company Delivering Global Access to the Entire Clinically-Actionable Genetic Test Menu

SAN DIEGO, CA--(Marketwire - Dec 4, 2012) - Invivoscribe Technologies, Inc., a privately-held life science company based in San Diego, California, announces the launch of Genection, Inc. ...